ClinicalTrials.gg
Active, not recruitingNCT07109414Updated Mar 9, 2026

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

A Phase 2/3 interventional study of NP-G2-044 and PLD in Platinum-resistant Ovarian Cancer, sponsored by Novita Pharmaceuticals, Inc.. Active, not recruiting at 6 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Novita Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.

Planned enrollment
4th of 42
380 · median 53
Started
2025
the only one that year
Phase 2/3
Only one
of the 42
Registered
42nd of 42
by date

Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 42nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms as a file.
02

Study summary

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).

Read the detailed description

This is an open-label, Phase 2/3, multicenter, randomized study of NP-G2-044 in combination with PLD vs. PLD alone in participants with PROC. The Phase 2 component of the study includes a safety lead-in dose escalation of NP-G2-044 monotherapy with twice daily (BID) dosing and a dose escalation phase for NP-G2-044+PLD followed by a randomized dose optimization phase of NP-G2-044+PLD compared with PLD. In the Phase 3 component of the study, participants will be randomized to treatment with NP-G2-044+PLD, at the dose selected from the dose optimization phase, or to PLD alone. Randomized participants will be stratified according to the number of prior lines of therapy, number of prior PLD therapy lines, and region of the world. The study population is women at least 18 years of age with confirmed ovarian high grade serous carcinoma, an Eastern Cooperative Oncology Group (ECOG) status of 0-1, and whose cancer is resistant to platinum-based therapy.

03

Conditions studied

  • Platinum-resistant Ovarian Cancer

Browse trials for

Keywords

  • Dose escalation
  • Dose optimization
  • Small-molecule fascin inhibitor
  • Advanced or metastatic ovarian cancer
  • Randomized Phase 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed ovarian high-grade serous carcinoma (histologically or cytologically)

    1. Participants should have platinum resistance
    2. No PLD use after developing platinum resistance
    3. Participants must have had bevacizumab in a prior treatment line or must have been ineligible for bevacizumab therapy.
  • status 0-1
  • per v1.1 as assessed by local site Investigator/radiologists in the Dose Escalation phase, and assessed by BICR in the Dose Optimization phase and Phase 3; lesions situated in previous irradiated areas are considered measurable if progression has been demonstrated in such lesions
  • > 50%
  • Participants with adequate hematologic function based on following

    1. ≥ 1.5 × 109/L
    2. count ≥ 100 × 109/L
    3. ≥ 9.0 g/dL
    4. Albumin ≥ 3.0 g/dL
  • Adequate coagulation parameters based on the following:

    1. -internationalization normal rate (INR)/partial thromboplastin time \< 1.5 × (ULN)
    2. Partial thromboplastin time or activated partial thromboplastin time \< 1.25 × ULN
  • Participants must have adequate hepatic and renal function. For hepatic function, total should be less than 1.5 times the ULN. For renal function, serum must be at least 45 mL/min.
  • Participants of (defined as sexually mature women who have not undergone surgical sterilization or been for at least 12 months if over 55 years of age) must have a negative pregnancy test within 72 hours before starting treatment. These participants must use highly effective or abstain from heterosexual activity from screening through 120 days after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Primary platinum- (recurrence within 120 days of platinum-containing therapy or during first-line platinum-containing therapy).
  • Recurrence greater than 183 days from the penultimate platinum (platinum-sensitive recurrent ovarian cancer).
  • Uncontrolled malignant pleural effusions and/or ascites as defined by a prior needle drainage within 60 days of first dose.
  • Major surgery within 4 weeks prior to Screening.
  • Prior radiotherapy within 4 weeks of start of study treatment.

    1. Participants must have recovered from all radiation-related toxicities, not require for their radiation therapy, and have no history of radiation pneumonitis.
    2. A 1-week is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
  • Anticancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or agents prior to administration of the first dose of study treatment.
  • Active ; participants with are not eligible.
  • Primary CNS .
  • Severe gastrointestinal conditions such as existing bowel obstruction defined as air fluid levels in the small bowel and/or intolerance to oral medications, clinical or radiological evidence of bowel obstruction within 8 weeks prior to study entry requiring hospitalization, current use of nasogastric tube decompression, inability to tolerate solid feedings or vomiting more than once a day.
  • Liver involving > 60% of liver parenchyma.
  • Known active infection with (HIV), Virus (HBV), or virus (HCV)
  • Requiring therapy
  • Evidence of ongoing systemic bacterial, fungal, or viral infections at Screening
  • Received a within 6 weeks of first dose of study drug.
  • Received a Coronavirus disease-2019 (COVID-19) vaccine less than 1 week prior to dosing (Cycle 1/Day 1) and/or during the study received a COVID-19 vaccine or booster less than 3 weeks ahead of a tumor assessment.
  • Baseline corrected with Fridericia's method (i.e., QTcF) > 470 ms.
  • Female participants who are pregnant or breastfeeding.
  • Concurrent active malignancy.
  • History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment.
  • History of stroke, unstable angina, myocardial infarction, congestive heart failure ( classification III or IV), left ventricular hypertrophy or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to Screening.
  • Participants with increased baseline risk of Torsades de Pointe due to:

    1. Electrolyte imbalance at screening (clinically significant hypokalemia, hypomagnesemia or hypocalcemia per Investigator's determination)
    2. Known congenital long QT syndrome (LTQS)
    3. Bradycardia (heart rate \< 50 beats per minute)
  • Unstable or severe uncontrolled medical condition like unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes or any important medical illness or abnormal laboratory findings
  • Grade 3 or 4 toxicity due to PLD in prior treatment.
  • Grade 2 or greater neuropathy
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Part A1 (Dose escalation):NP-G2-044 Monotherapy

    Participants will receive multiple doses of NP-G2-044 in tablet form orally as a monotherapy twice a daily.

    Drug: NP-G2-044

  • Experimental
    Part A2 (Dose escalation): NP-G2-044+PLD combination therapy

    Participants will receive multiple doses of NP-G2-044 (once daily \[QD\] or BID) in tablet form orally plus a single dose of PLD as an infusion via intravenous route once in every 28 days. The recommended monotherapy doses of NP-G2-044 are determined from the results of Part A1.

    Drug: NP-G2-044 · Drug: PLD

  • Experimental
    Part B (Dose optimization): NP-G2-044+PLD combination dose level 1

    Participants will receive daily dose of NP-G2-044 in tablet form orally plus a single dose of PLD as an infusion via intravenous route once in every 28 days.

    Drug: NP-G2-044 · Drug: PLD

  • Experimental
    Part B (Dose optimization): NP-G2-044+PLD combination dose level 2

    Participants will receive daily dose of NP-G2-044 in tablet form orally plus a single dose of PLD as an infusion via intravenous route once in every 28 days.

    Drug: NP-G2-044 · Drug: PLD

  • Active comparator
    Part B (Dose optimization) :PLD

    Participants will receive a single dose of PLD as an infusion via intravenous route alone once in every 28 days.

    Drug: PLD

  • Experimental
    Part C (Phase 3): NP-G2-044+PLD

    Participants will receive daily dose of NP-G2-044 in tablet form orally plus a single dose of PLD as an infusion via intravenous route once in every 28 days.

    Drug: NP-G2-044 · Drug: PLD

  • Active comparator
    Part C (Phase 3): PLD

    Participants will receive a single dose of PLD as an infusion via intravenous route once in every 28 days.

    Drug: PLD

Interventions

  • NP-G2-044 will be provided as a tablet via oral route of administration in the study.

    Also known as: Prilukae

  • DrugPLD

    PLD will be provided as an infusion via intravenous route of administration in the study.

06

What researchers measure

Primary outcomes

  1. Part A (Dose escalation): Number of participants with adverse events (AEs)

    The safety and tolerability of NP-G2-044 monotherapy with BID dosing and in combination with PLD will be evaluated

    Time frame: From first dose until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) Approximately 2 years

  2. Part A (Dose escalation): Number of participants with Dose Limiting Toxicities (DLTs)

    The safety and tolerability of NP-G2-044 monotherapy with BID dosing and in combination with PLD and to determine the recommended Phase 2 dose (RP2D) of NP-G2-044 when combined with PLD will be determined

    Time frame: Up to 28 days

  3. Part B (Dose Optimization): Number of participants with AEs

    The safety and tolerability of the treatment groups will be compared.

    Time frame: From Day 1 until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) Approximately 2 years

  4. Part B (Dose Optimization): Overall response rate (ORR)

    The optimal dose of NP-G2-044 combined with PLD will be evaluated. The ORR is defined as the proportion of participants with complete response (CR) or partial response (PR).

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 2 years)

  5. Part B (Dose Optimization): Progression free survival (PFS)

    The optimal dose of NP-G2-044 combined with PLD will be evaluated. The PFS is defined as time from randomization until adequately documented disease progression based on blinded independent committee review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death, whichever occurs first.

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 2 years)

  6. Part C (Phase 3): Progression free survival (PFS)

    The efficacy of NP-G2-044 when combined with PLD vs. PLD alone will be compared. The PFS is defined as time from randomization until adequately documented disease progression based on BICR per RECIST v1.1 or death, whichever occurs first.

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 3 years

Secondary outcomes

  1. Part A (Dose Escalation) and Part C (Phase 3): Overall response rate (ORR)

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. The ORR is defined as the proportion of participants with CR or PR.

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (For Part A: Approximately 2 years; Part C: Approximately 3 years)

  2. Part A (Dose Escalation): Progression free survival (PFS)

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. The PFS is defined as time from start of treatment until adequately documented disease progression based on local assessment of imaging studies, or death, whichever occurs first.

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (For Part A: Approximately 2 years; Part C: Approximately 3 years)

  3. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Gynecologic Cancer Intergroup Cancer antigen-125 (GCIG CA-125) criteria for response

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. A response according to CA-125 has occurred if there is at least a 50% reduction in CA-125 levels from a pretreatment sample. The response must be confirmed and maintained for at least 28 days. Participants can be evaluated according to CA-125 only if they have a pretreatment sample that is at least twice the upper limit of normal and within 2 weeks prior to starting treatment. The date when the CA-125 level is first reduced by 50% is the date of the CA-125 response. To calculate CA-125 responses accurately, the following rules apply: 1) Intervening samples and the 28-day confirmatory sample must be less than or equal to (within an assay variability of 10%) the previous sample. 2) Variations within the normal range of CA-125 levels will not interfere with the response definition.

    Time frame: From Screening to survival follow-up (until progression, death, or withdrawal of consent) (For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  4. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Overall survival (OS)

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. The OS is defined as time from start of treatment until death.

    Time frame: From randomization until death For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  5. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Disease control rate (DCR)

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. The DCR is defined as the proportion of participants with confirmed CR, PR or stable disease (SD).

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  6. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Duration of response (DOR)

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. The DoR is defined as the time from first CR or PR to disease progression or death in participants who achieve CR or PR.

    Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  7. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Metastasis-free interval (MFI)

    The initial efficacy of NP-G2-044 in combination with PLD will be evaluated. The MFI is defined as the time from start of treatment to confirmed occurrence of new metastasis.

    Time frame: From treatment initiation to confirmed occurrence of new metastasis (For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  8. Part A (Dose Escalation) and Part C (Phase 3): Number of participants with AEs

    The safety and the tolerability of the treatment groups will be compared.

    Time frame: From Day 1 until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  9. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Participant reported outcomes based on European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire-Ovarian Cancer Module 28 (EORTC QLQ-OV28)

    The treatment groups for participant reported Quality of life (QoL) will be compared. The EORTC QLQ-OV28 will evaluate the QoL with respect to ovarian cancer. The EORTC QLQ-OV28 is specific for ovarian cancer and consists of 28 items. Each scale was scored from 0 to 100 with higher scores on the symptom scales indicating greater symptom burden.

    Time frame: At screening, every 3 cycles starting Cycle 1 Day 1 (each Cyle is 28 days) For Part A and B: (Approximately 2 years; Part C: Approximately 3 years)

  10. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Participant reported outcomes based on European Quality of Life -5 Dimensions -5 Levels (EuroQol EQ-5D-5L)

    The treatment groups for participant reported QoL will be compared. The EQ-5D-5L questionnaire assess health outcome from a wide variety of interventions on a common scale. It is comprised of 5 dimensions where each dimension has 5 levels. A higher score represents a worse outcome.

    Time frame: At screening, every 3 cycles starting Cycle 1 Day 1 (each Cyle is 28 days) (For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  11. Part A (Dose Escalation), Part B (Dose optimization) and Part C (Phase 3): Participant reported outcomes based on Functional Assessment of Cancer Therapy Ovarian Symptom Index (FOSI)

    The treatment groups for participant reported QoL will be compared. The FOSI 8-item questionnaire measures response to treatment based on symptom assessment. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic).

    Time frame: At screening, every 3 cycles starting Cycle 1 Day 1 (each Cyle is 28 days) (For Part A and B: Approximately 2 years; Part C: Approximately 3 years)

  12. Part A (Dose Escalation) and Part B (Dose optimization): Terminal half-life (T1/2) of NP-G2-044 and PLD

    The T1/2 of NP-G2-044 as a monotherapy with BID dosing and NP-G2-044 and PLD as combination therapy will be evaluated.

    Time frame: From Day 1 to End of treatment (Approximately 2 years)

  13. Part A (Dose Escalation) and Part B (Dose optimization): Time to maximum plasma concentration (Tmax) of NP-G2-044 and PLD

    The Tmax of NP-G2-044 as a monotherapy with BID dosing and NP-G2-044 and PLD as combination therapy will be evaluated.

    Time frame: From Day 1 to End of treatment (Approximately 2 years)

  14. Part A (Dose Escalation) and Part B (Dose optimization): Maximum plasma concentration (Cmax) of NP-G2-044 and PLD

    The Cmax of NP-G2-044 as a monotherapy with BID dosing and NP-G2-044 and PLD as combination therapy will be evaluated.

    Time frame: From Day 1 to End of treatment (Approximately 2 years)

  15. Part A (Dose Escalation) and Part B (Dose optimization): Area under the plasma concentration-time curve (AUC) of NP-G2-044 and PLD

    The AUC of NP-G2-044 as a monotherapy with BID dosing and NP-G2-044 and PLD as combination therapy will be evaluated.

    Time frame: From Day 1 to End of treatment (Approximately 2 years)

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Oct 25, 2028
CompletionEst.
Oct 24, 2029
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109414
Lead sponsor
Novita Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Dec 29, 2025
Primary completion
Oct 25, 2028 (estimated)
Completion
Oct 24, 2029 (estimated)
Last update
Mar 9, 2026

Study contacts

Jillian Zhang, PhD
study director · Novita Pharmaceuticals, Inc.
Lisa Barroilhet, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: NP-G2-044 · Liposomal doxorubicin

Start the discussion